92 results
Primary objectivesTo characterize the bone marrow microenvironment in advanced stage myelofibrosis (MF) before and during treatment with ruxolitinib, regarding osteoblastic activity, marrow fibrosis and - osteosclerosis and perfusion- and diffusion…
Part I: Evaluate the safety and tolerability of selinexor at 3 different dose levels in combination with bortezomib/dexamethasone & determine recommended dose level (RDL) of selinexor for Part IIPart II: Evaluate the efficacy of the…
We here wish to apply new advancements in multi-color flow cytometry for a detailed and sensitive examination of mast cells in peripheral blood of patients with SM.
The aim of our study is to assess the prevalence of cardiac dysfunction and undiagnosed heart failure in women registered in general practice with a history of breast cancer who received chemotherapy and / or radiotherapy as compared to a matched…
The primary objective of this study will be:* To determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractoryPTCL;The secondary objectives of this study will be:* To determine the duration of response,…
During the last several years, substantial progress has been made regarding the biologic characterization of the acute leukemias. The traditional understanding that myeloid leukemic cells are developmentally similar to their normal hematopoietic…
The primary objective is to compare the efficacy of two dose-schedule arms(s) of pacritinib (pooled once daily [QD] and twice-daily [BID] dosing arms) with that of best available therapy (BAT) in patients with thrombocytopenia and primary…
Primary: To study the efficacy and tolerability of Midostaurin in patients with indolent or smoldering systemic mastocytosis on mediator symptom reduction.Secondary: 1) To study whether Midostaurin can reduce mast cell infiltration and 2) to assess…
Primary Objective:The primary objective of this study is to demonstrate that CNTO 328 in combination with BSC is superiorto BSC in terms of objective response (complete response [CR] + partial response [PR]) among subjectswith multicentric Castleman…
The primary objective of this study is to determine if there is an improvement in progression-free survival(PFS) when siltuximab is added to VELCADE* (bortezomib) and dexamethasone in subjects with relapsedor refractory multiple myeloma.The…
The aim of the current study is to improve the diagnosis of iron overload in MDS patients. The primary objectives are to evaluate 1. the relationship between red blood cell transfusions and iron overload in liver and heart as investigated by MRI T2…
Compare efficacy and safety ofpomalidomide versus placebo in reversing RBC-transfusiondependence in subjects with MPN-associated myelofibrosis and RBC-transfusion-dependence. Investigate variables correlated with RBC-transfusion-independence and/or…
To evaluate the efficacy of romiplostim for the treatment of thrombocytopenia in subjects with international prognostic scoring system (IPSS) low or intermediate-1 risk MDS as measured by the number of clinically significant bleeding events.
The primary objective is to compare PFS after treatment with tabalumab, bortezomib, anddexamethasone to that of placebo, bortezomib, and dexamethasone in patients with relapsed/refractory MM.Secondary objectives will include comparison of treatment…
1. To evaluate efficacy of vorinostat in the treatment of patients with polycythaemia vera (PV) and essential thrombocythaemia (ET) 2. To evaluate if vorinostat as monotherapy of patients with PV and ET is followed by a decline in clonal…
This proposed study has three main objectives:1. To determine the feasibility of intra-marrow transplantation (IMT) of MSCs in lower risk MDS patients (a Phase I/II study):Although we have experience with application of (unrelated) MSCs and intra-…
The primary objective is to compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone as measured by progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM). Secondary objectives…
To study (in vitro) if dendritic cells can be cultured with cells obtained from peripheral blood of patients with either m. myeloma, ovarian cancer or breast cancer. Thusfar we worked with cells from healthy volunteers. Before performing clinical…
The family, described in a publication from 1987, is recently re-identified. It seems to be an asymptomatic condition: there seems to be no anemia or secondary iron overload. Again mapping this family has two purposes:1. Have these patients…
The primary objective of this study is:To determine the response rate [the combined complete response (CR) + partial response (PR) + minimal response (MR)] following treatment with BDR in patients with previously untreated WM.Secondary objectives…